NASDAQ:OPGN - OpGen Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $1.80 0.00 (0.00 %) (As of 08/17/2018 06:00 AM ET)Previous Close$1.80Today's Range$1.76 - $1.8452-Week Range$1.62 - $10.25Volume41,927 shsAverage Volume384,128 shsMarket Capitalization$10.99 millionP/E Ratio-0.18Dividend YieldN/ABeta1.5 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland. Receive OPGN News and Ratings via Email Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical SymbolNASDAQ:OPGN CUSIPN/A Webwww.opgen.com Phone240-813-1260 Debt Debt-to-Equity Ratio0.19 Current Ratio2.13 Quick Ratio1.99 Price-To-Earnings Trailing P/E Ratio-0.18 Forward P/E Ratio-0.85 P/E GrowthN/A Sales & Book Value Annual Sales$3.21 million Price / Sales3.48 Cash FlowN/A Price / CashN/A Book Value$0.62 per share Price / Book2.90 Profitability EPS (Most Recent Fiscal Year)($9.78) Net Income$-15,410,000.00 Net Margins-373.39% Return on Equity-261.32% Return on Assets-124.09% Miscellaneous Employees43 Outstanding Shares6,210,000Market Cap$10.99 million OpGen (NASDAQ:OPGN) Frequently Asked Questions What is OpGen's stock symbol? OpGen trades on the NASDAQ under the ticker symbol "OPGN." When did OpGen's stock split? How did OpGen's stock split work? Shares of OpGen reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split. How were OpGen's earnings last quarter? OpGen Inc (NASDAQ:OPGN) released its quarterly earnings results on Thursday, August, 2nd. The medical research company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.03. The medical research company earned $0.79 million during the quarter, compared to analyst estimates of $0.79 million. OpGen had a negative return on equity of 261.32% and a negative net margin of 373.39%. View OpGen's Earnings History. When is OpGen's next earnings date? OpGen is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for OpGen. What price target have analysts set for OPGN? 1 brokers have issued 1-year target prices for OpGen's stock. Their forecasts range from $8.00 to $8.00. On average, they expect OpGen's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price. View Analyst Price Targets for OpGen. What is the consensus analysts' recommendation for OpGen? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen. Who are some of OpGen's key competitors? Some companies that are related to OpGen include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Foundation Medicine (FMI), Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), CareDx (CDNA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Psychemedics (PMD). Who are OpGen's key executives? OpGen's management team includes the folowing people: Mr. Evan Jones, Chairman & CEO (Age 61)Mr. Timothy C. Dec, CFO, Principal Accounting Officer & Corp. Sec. (Age 59)Mr. Vadim Sapiro, Chief Information Officer (Age 47)Mr. Michael Farmer, VP of MarketingDr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 59) When did OpGen IPO? (OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager. Has OpGen been receiving favorable news coverage? Media coverage about OPGN stock has trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OpGen earned a news and rumor sentiment score of 0.09 on Accern's scale. They also gave headlines about the medical research company an impact score of 47.92 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for OpGen. Who are OpGen's major shareholders? OpGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include B. Riley Financial Inc. (2.22%) and Acadian Asset Management LLC (0.99%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen. Which institutional investors are buying OpGen stock? OPGN stock was purchased by a variety of institutional investors in the last quarter, including B. Riley Financial Inc. and Acadian Asset Management LLC. Company insiders that have bought OpGen stock in the last two years include Jven Capital, Llc and Timothy C Dec. View Insider Buying and Selling for OpGen. How do I buy shares of OpGen? Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OpGen's stock price today? One share of OPGN stock can currently be purchased for approximately $1.80. How big of a company is OpGen? OpGen has a market capitalization of $10.99 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe. How can I contact OpGen? OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected] MarketBeat Community Rating for OpGen (NASDAQ OPGN)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 159 (Vote Outperform)Underperform Votes: 172 (Vote Underperform)Total Votes: 331MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/17/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?